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The biological properties of immune complexes depend 
on the nature of antigens and antibodies comprising 
these complexes. The lattice of immune complexes influ-
ences t h eir tissue deposition, complement activation, 
and interaction with Fe receptors. The lattice of immune 
complexes depends on the valence of antigens, the anti-
gen-antibody ratio, the association constant of these 
reactants and the concentration of antig~n and antibody. 
Kupffer cells effectively remove large- latticed immune 
complexes from the circulation due to their Fe receptors. 
This system is saturable, leading to prolonged circula-
tion of the complexes a nd enhanced deposition in tissues. 
Small-latticed immune complexes are slowly removed 
from the circulation by yet unidentified mechanisms. 
The renal glomerulus serves as an example of immune 
complex deposition from the circulation. Only large-lat-
ticed complexes are deposited in the glomerular capil-
lary wall in the subendothelial area and the m esangial 
matrix. An influx of bone marrow-derived monocytes 
participates in the disposal of immune complexes depos-
ited in these areas of the glomerulus, the resident mes-
angial cells do not phagocytize these substances. The 
subepithelial d eposits of immune complexes appear to 
be locally formed and not deposited from the circulation. 
Immune complexes cause a variety of clinical disorders, af-
fecting various sizes of blood vessels, renal glomeruli, renal 
t ubules, thyroid gland, choroid plexus and other organs. The 
pathogenic immune complexes are either deposited from the 
circulation or locally formed. In local formation of immune 
complexes the antigens are par t of the · organ or unrelated 
ant igens are selectively deposited in the organ and antibodies 
from the circulation react with these antigens. In this patho-
genic mechanism characteristically one organ system is in-
volved and immune complexes are not present in the circula-
tion. On the other hand, when immune complexes are present 
in the circula tion, usually more than one organ is involved due 
to deposition of these materials from circulation. In this a1·ticle 
the nature and biological properties of immune complexes will 
be briefly reviewed. The relationship between the composition 
of immune complexes and their fate in cil:culation will be 
discussed with particular emphasis on the ro le of the mononu-
clear phagocyte system in removal of circulating immune com-
plexes. Since detailed experimental data ar e not available on 
the relationship between the composition of immune complexes 
and their deposition in skin, this relationship will be examined 
for renal glomeruli. 
THE NATURE AND PROPERTIES OF IMMUNE 
COMPLEXES 
Antigens and antibodies aTe the essential constituents of all 
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immune complexes. In any given immune complex the number 
of antigen and antibody molecules may vary, depending on the 
characteristics of each of the reactants and the nature of the 
antigen-antibody union. The biological properties of immune 
complexes are related to the properties of the molecules forming 
the complexes, as well as the number of reactants in each 
complex. 
Antigens are defined as substances that interact specifically 
with availa ble antibodies or sensitized lymphocytes. The term 
immunogen, on the other hand, is reserved for a substance that 
upon administration to a suitable host will elicit an immune 
response. This distinction is made because all substances that 
react with antibodies or with sensit ized lymphocytes do not 
necessarily induce an immune response. The actual portion of 
an antigenic molecule that reacts with the antibody combining 
site or with the specific receptor on a sensitized lymphocyte is 
defined as the antigenic determinant. The number of antigenic 
determinants on a molecule defines its valence for the in terac-
tion wi th a specific antibody. An antigenic molecule may have 
the valence of one for a given antibody specificity, but a number 
of naturally occurring molecules have repeating chemical struc-
tuTes, thus giving an ant igenic valence of more than one. Fur-
th~rmore, a given molecule may have different ant igenic deter-
minants and thus able to react with antibodies of different 
specificities. Thus, a macromolecule may be mutivalent with 
respect to one or more specificities. The number of ant igenic 
determinants of a molecule profoundly influences the kind of 
antigen-antibody complexes that may form with specific anti-
bodies. For detailed discussion of antigens and antigenic deter-
minants the interested reader should consul t immunochemical 
texts (1 , 2]. 
Antibodies, as the other essential constituents of immune 
complexes, may belong to IgG, IgA, IgM, IgD or IgE class of 
immunoglobulins. IgG, monomeric IgA, IgD and IgE have a 
valence of 2, i.e., each of these molecules has 2 binding sites for 
a given antigen . Dimeric IgA has a valence of 4. lgM has a 
valence of 5 or 10, depending on th e nature of antigen molecules. 
For detailed discussion of various antibody molecules, the 
reader should consult appropriate reviews [1,3,4]. 
When the antigen-antibody union occurs, a variety of im-
mune complexes m ay form, ranging from an immune complex 
consisting of 1 antigen molecule and 1 sntibody m olecule (Ag~, 
Abt) to immune complexes consisting of many molecules of 
each reactan t. The lattice of immune complexes thus reflects 
the number of antigen and number of antibody molecules in 
each complex. T he lattice of an immune complex in turn 
influences its biological properties. 
The lattice of immune complexes is influenced by several 
variables. As all·eady pointed out, the valence of most antibodies 
is 2. Detailed studies with polymeric IgA and IgM have not 
been conducted. The valence of ant igen molecules significantly 
influences the lattice of immune complexes that can be formed 
with given antibodies. A monovalent antigenic molecule can 
only form Ag2Ab1 complexes and larger lattices or immune 
precipitates can not be generated. Bivalent antigens, depending 
on the distance between the antigenic determinants, may form 
Ag tAb ~, Ag2Abz, cil'cular Ag3Ab3 or larger open or closed com-
plexes [5]. Such small-latticed immune complexes are soluble. 
Only multivalent an tigens can form immune complexes with 
high degrees of lattice and undergo immune precipitation. 
With multivalent antigens the molar ratio of antigens and 
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antibodies influence t he degree of lattice formation as best 
illustrated by the classic precipitin curves. At the point of 
equivalence maximum amount of antigen-antibody precipitate 
is formed and free antigen and free ant ibody are not detectable 
in the supernatant. Addition of excess antigen beyond the point 
of equ ivalence leads to formation of soluble immune complexes 
and a decrease in the amount of immune precipitate. At rela-
tively low degrees of antigen excess soluble large-latticed im-
mune complexes are formed, but with increasing addition of 
excess antigen only small-latticed immune complexes are ob-
tained. For example, with high degrees of excess human serum 
albumin (subsequently abbreviated HSA) to a given amount of 
antibodies to HSA only Ag,Ab, and Ag2Ab2 complexes were 
formed [6]. Fw·thermore, the absolute concentration of antigen 
and antibody will influence the degree of lattice formation. At 
a given degree of antigen excess more small-latticed immune 
complexes are formed at microgram concentrations of the reac-
tants than at the same antigen-antibody ratio in milligram 
concentration of the reactants. 
The association constant between the antigen and antibody 
will influence lattice formation. When the association constant 
is low, small-latticed immune complexes tend to be formed, 
whereas large-latticed immune complexes can form when the 
association constant is high and the antigen-antibody ratio is 
appropriate [7]. 
The immunochemical characteristics of immune complexes 
in human diseases have not been examined in sufficient detail 
to relate their features to the disease processes and disease 
outcome. As will be discussed below, the lattice of immune 
complexes influences the fate and tissue deposition of these 
materials in experimental animals. 
The biological properties of immune complexes relevant to 
immune complex diseases are deposition in tissues, activation 
of the complement systems and interaction with cell receptors. 
These properties of immune complexes depend on the class and 
subclass of antibodies in the complexes, the degree of lattice 
formation and to a lesser degree, on the properties of antigens 
in the complexes. Other biologic properties of immune com-
plexes, including their influence on the immune response of the 
host and alterations of lymphocyte functions, are less well 
understood on the molecular level at this time, but have been 
reviewed elsewhere [8]. 
Deposition of immune complexes in tissues will be discussed 
below. A detailed discussion of the mechanisms of complement 
activation are beyond the scope of this review, but other sources 
are available [9,10]. Human IgG1, IgG2, and lgG3 are effective 
in activating the classical complement pathway, whereas lgG4 
is ineffective. Among the other classes of im.munoglobulins only 
IgM can activate the complement system through the classical 
pathway. The alternative complement pathway is also activated 
by the same subclasses and classes of antibodies that activate 
the system through the early complement components. This 
activation occurs through the C3b-dependent loop of the alter-
native pathway. Effective complement activation occurs when 
the lattice of immune complexes contains more that 2 or 3 IgG 
molecules. The molecular mechanisms for complement com-
ponent binding and activation an not yet settled [11,12]. 
Fe receptors (also called IgG receptors) mediate the interac-
tion of immune complexes with neutrophils, monocytes (includ-
ing tissue macrophages and Kupffer cells), platelets and certain 
T and B lymphocyte populations. These receptors are specific 
for immunoglobulin G and do not interact with other classes of 
immunglobulins. The Cy3 domain (third constant homology 
region) of the lgG molecules interacts with this receptor [ 4]. In 
addition to the Fe receptors, phagocytic cells and some lym-
phocytes possess complement receptors. Mouse monocytes pos-
sess 2 distinct Fe receptors, one for aggregated IgG and one for 
the IgG2a subclass of mouse IgG [13]. Such differences have 
not yet been defined for human monocyte receptors. 
The lattice of immune complexes influences their interaction 
with the Fe receptors of phagocytic cells. Monomeric IgG 
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molecules attach to these receptors weakly, but do not lead to 
interiorization of the molecules. Attachment of large-latticed 
complexes (defined as containing more than 2 antibody mole-
cules) results in firmer attachment of the complexes and cul-
minates in their phagocytosis. Evidence for these conclusions 
has been obtained by examining complexes with oligovalent 
and multivalenc antigens [14], immune complexes with known 
degrees of lattice formation [15,16], and with covalently cross-
linked immune complexes with discrete degrees of lattice for-
mation [17]. Complement is not essential for the attachment of 
soluble immune complexes to the Fe receptor of monocytes 
[15]. The phagocytosis and degradation of soluble immune 
complexes, however, was facilitated by the presence of comple-
ment [18]. 
The interaction of soluble immune complexes, containing IgG 
molecules, with the Fe receptors is of fu ndamental importance 
to the fate of immune complexes in circulation, as will be 
discussed in the next section. Furthermore, during the phago-
cytosis of large-latticed immune complexes, particularly when 
these substances are attached to nonphagocytizable surface, 
lysosomal enzymes spill in to the surroundings. This event is 
thought to be important in leading to t issue damage after 
immune complex deposition or formation in tissues. The phag-
ocytosis of immune complexes also causes activation of macro-
phages with addi tional biologic properties as discussed earlier 
in this workshop. 
THE FATE OF CIRCULATING IMMUNE COMPLEXES 
The concentration of immune complexes in circulation at any 
given time depends on the rate of immune complex formation 
and on the rate of immune complex removal. The rate of 
immune complex formation is a function of the availabili ty of 
specific antigens and antibodies to these antigens. In human 
diseases and in spontaneous animal models these variables have 
not been quantified. The rate of immune complex removal from 
circulation is a function of uptake of immune complexes by the 
mononuclear phagocyte system (formerly termed the reticulo-
endothelial system) and deposition of immune complexes in 
tissues. Quantitative studies in antigen-induced acute or chronic 
serum sickness models disclosed that only very small propor-
tions of antigen were deposited in renal glomeruli during the 
disease process [19], yet these small amounts of immune com-
plexes sufficed to cause t issue damage and organ failure . 
The fate of immune complexes in circulation has been ex-
amined quantitatively by the injection of preformed immune 
complexes with known degrees of lattice formation. These 
studies have been confined to the IgG class of antibodies. The 
fate of circulating immune complexes was examined in unim-
munized mice [20,21], rabbits [22,23], and monkeys [24] by 
injection of preformed immune complexes. The lattice of im-
mune complexes, the status of the mononuclear phagocyte 
system (subsequently abbreviated MPS), the nature of antigens 
in immune complexes and the nature of antibodies in immune 
complexes alter the uptake of immune complexes by the MPS. 
Large-latticed immune complexes, defined as containing 
more than 2 antibody molecules (greater than Ag2Ab2) were 
removed relatively rapidly when injected into unimmunized 
mice [20,21], rabbits [22,23] or monkeys [24]. The disappear-
ance of these complexes was described by a single exponential 
function. The half-life of these large-latticed complexes was 
related to the dose of injected materials; with increasing dose 
the rate of removal of these complexes decreased, and the 
clearance velocity of large-latticed immune complexes reached 
a plateau, indicating saturation of the system [20]. The major 
organ for the uptake of the large-latticed circulating immune 
complexes was the liver in mice, rabbits, and monkeys 
[20,23,24]. As increasing doses were injected, also specific he-
patic uptake reached a plateau, providing independent evidence 
for the saturation of the uptake of circulating immune com-
plexes by the liver [20]. Kupffer cells are responsible for the 
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hepatic uptake of immune complexes and with increasing doses 
of complexes the Fe receptors are saturated. Kupffer cells are 
derived from bone-marrow monocytes [25] and uniquely suited 
for cleru·ance of circulating materials since the hepatic sinusoids 
lack endothelial cells, thus leaving the Kupffer cells directly 
exposed to circulating substances [26]. The saturability of the 
MPS by other circulating materials, not dependent on Fe 
receptors, is well established [27 ,28]. 
The role of the complement system in hepatic removal of 
circulating immune complexes was examined by depleting com-
plement components with cobra venom factor or with aggre-
gated human IgG in rabbits and administering small doses of 
preformed soluble immune complexes. The clearance kinetics 
[22] and quantitative hepatic uptake [23] were not altered as 
compru·ed with control animals. Furthermore, the administra-
tion of large doses of immune complexes to mice treated with 
cobra venom factor showed no alteration of the kinetics of 
removal of preformed, soluble immune complexes, (Bockow B, 
Mannik M: unpublished observations), as compru·ed to un-
treated mice. 
With the injection of small doses of immune complexes into 
rabbits, the splenic uptake accounted for less than 1% of im-
mune complexes removed from the circulation [23]. With lru·ge, 
saturating doses of immune complexes the specific splenic up-
take increased to 10% of the amount taken up by the liver 
[21]. On the other hand, antibody-sensitized red cells are pri-
marily taken up by the spleen, mediated through the Fe recep-
tors [29]. With this system saturation of splenic uptake has 
been found in human immune complex diseases [30] (reviewed 
by Lawley in this workshop). The saturation of the hepatic 
uptake of immune complexes, however, has not yet been ex-
amined in human disorders but has been documented in a 
chronic immune complex disease of mice with aggregated IgG 
as a surrogate for immune complexes [31]. 
The small-latticed immune complexes, defined as containing 
1 or 2 antibody molecules (i.e., Ag2Abz, Ag2Ab1 or Ag1Ab1) were 
removed more slowly from the circulation than large-latticed 
immune complexes, but faster than antibodies alone 
[21,22,24]. The fate of these materials was best described by 
exponential curves composed of 2 components. The flrst expo· 
nential component was attributed to equilibration between the 
intra- and extravascular spaces. The second exponential com-
ponent was ascribed to catabolism. The site of catabolism and 
the physiological consequences of these complexes have not 
been fully explored. Of note is that even the catabolic site of 
IgG has not yet been established. The conclusion on the fate of 
immune complexes, reached by injection of preformed immune 
complexes with known degrees of lattice formation, have been 
supported by experiments where isolated complexes with vru-y-
ing degrees of lattice formation were injected into animals. In 
these experiments the re-equilibration of complexes was 
avoided by covalent cross-linking of the antigen and antibody 
(Mannik et al: unpublished observations) [32]. 
As already noted above, the injection of increasing doses of 
large-latticed immune complexes results in saturation of the 
removal kinetics and saturation of the specific hepatic uptake 
of these materials [20]. With saturation of removal kinetics the 
large-latticed complexes circulate longer and the tissue locali-
zation ofthese materials is enhanced, as demonstrated for renal 
glomeruli [33]. Other variables that might alter the functional 
capacity of the MPS for the uptake of immune complexes have 
not been examined. The functions of the MPS system in relation 
to human diseases need fwther explorations. 
The influence of various antigens on the fate of immune 
complexes has not been cru·efully examined. Several studies 
indicate that the natme of antigens in immune complexes can 
alter the fate of these materials. For example, heavily dinitro-
phenylated bovine serum albumin was rapidly removed from 
the blood of unimmunized animals [34]. Similarly, human se-
rum albumin conjugated with 4-fluoro·3-nitrophenyl azide was 
removed with increasing rapidity from the blood of unimmu-
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nized mice as a function of the epitope density [35]. Small-
latticed immune complexes prepared with highly conjugated 
antigen were also removed faster from circulation than similar 
complexes prepared with minimally col).jugated antigen [36]. 
These observations indicate that the antigen can influence the 
fate of immune complexes independent of the lattice structure. 
The fate of immune complexes in circulation can be altered 
by the nature of antibodies in the complexes. Human IgA and 
IgG2 and IgG4 are ineffective in interacting with the Fe receptor 
of phagocytic cells [9]. Therefore, immune complexes contain-
ing these antibodies might persist longer in circulation than 
complexes containing antibodies that react effectively with Fe 
receptors. Support for this possibility was obtained by exam-
ining the fate of immune complexes prepared with IgG mole-
cules with reduced and alkylated interchain disulfide bonds. 
Such antibodies formed lattice structures complarable to com-
plexes made with intact antibody molecules [22]. Immune com-
plexes prepared with reduced and alkylated IgG molecules 
reacted ineffectively with monocyte receptors in vitro [15]. 
When complexes with reduced and alkylated antibodies were 
injected into mice [21], rabbits [22,23], or monkeys [24], the 
large-latticed immune complexes persisted in circulation due to 
decreased hepatic uptake and were removed at rates compa-
rable to small-latticed immune complexes. As a result of pro-
longed circulation of these materials, increased glomerular dep-
osition occurred [33]. 
GLOMERULAR DEPOSITION OF IMMUNE 
COMPLEXES 
The development of glomerulonephritis due to immune com-
plexes is well established experimentally. The presence of im-
mune complexes in glomeruli in human diseases is ext~msively 
documented. About 80 percent of glomerulonephritis appears 
to be caused by immunologic mechanisms. Only about 10 
percent of these result from antibodies to the glomerular base-
ment membrane (Goodpasture's syndrome) and the remainder 
ru·e caused by immune complexes [37]. In Goodpastme's syn-
drome the antibodies to the glomerular basement membrane 
ru·e diffusely localized on the basement membrane by immu-
nofluorescence microscopy. In contrast, immunofluorescence 
microscopy reveals lumpy-bumpy deposits along the glomerular 
basement membrane in glomerulonephritis caused by immune 
complexes. 
In human diseases and in experimental models immune com-
plexes ha~e be~n recognized in the subendothelial, mesangial, 
and subep1thehal areas of glomeruli. In a given disease, such as 
systemic lupus erythematosus, complexes may exist in all these 
areas to varying degrees. Furthermore, in the chronic serum 
sickness I_D<?del. of glomerulonephritis in rabbits, induced by 
repeat~d IDJectwns of bovine serum albumin, complexes were 
found m all 3 areas [38]. In these experiments the size of 
immune complexes in the circulation after antigen administra-
tion ~as related to t~e location of immune complexes in glo-
meruli. The conclusiOn was reach ed that the large-latticed 
complexes deposited in mesangial and subendothelial areas and 
relatively small-latticed complexes localized in the subepithelial 
area of glomerular capillary loops. These studies, however, did 
not provide di.re~t proof for the deposition of circulating im-
mune complexes m the subepithelial area. 
Intravenous injection of preformed soluble immune com-
plexes in to unimmunized mice has established that only large-
latticed complexes are deposited in the subendothelial and 
mesangial areas. Several lines of evidence support this conclu-
sion. When mixtures of large-latticed and small·latticed im-
mune complexes were administered, the deposit ion in glomeruli 
occurred only during the circulation of large-latticed inm1llne 
complexes [33]. When only small-latticed immune complexes 
were injected, prepared in 50-fold antigen excess, no glomerular 
deposition was found [35]. Subepithelial deposits, however, 
were never found in these experiments and by other investiga-
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Resolution of glomerular immune complexes by administration of 
excess antigen, demonstrated by immunofluorescence microscopy. At 
time 0 mice received HSA-antiHSA immune complexes prepared with 
reduced and ·a]kylated rabbit antibodies. The kidney sections in (A) 
and (C) were obtained from a mouse sacrificed at 24 hr for control 
purpose. The kidney sections in (B) and (D) were obtained from a 
mouse given 40-fold excess antigen (HSA) at 12 hr and sacrificed at 24 
hr. Section (A) and (B) were stained with sheep antibodies to rabbit 
lgG, conjugated with flu orescein isothiocyanate-(A) shows 4+ staining 
and (B) shows no staining. Sections (C) and (D) were stained with 
rabbit antibodies to HSA, conjugated wtih flu erescein isothiocyanate-(C) shows 3+ staining and (D) shows no staining. With the excess 
antigen administration both antigen and antibody were removed from 
the glomeruli. 
tors in sim.ilar studies [7,39], suggesting that circulating small-
latticed immune complexes did not reach this area during the 
course of experiments up to 96 hr. Experiments with adminis-
tration of excess antigen after the administration of immune 
complexes showed that when the deposited immune complexes 
were converted in vivo to small-latticed immune complexes, 
they were released from the glomeruli [ 40]. In these experi-
ments soluble immune complexes were injected into unimmu-
nized mice, 12 hr was allowed for glomerular deposition of 
immune complexes and then a 40-fold excess dose of antigen 
was given and mice were serially sacrificed. By 12 hr after the 
injection of excess antigen no antibody or antigen could be 
detected in glomeruli by immunofluorescence microscopy (see 
Figure). Electron microscopy showed no electron dense deposits 
in these specimens. Control mice sacrificed at the same time 
showed abundant deposits. These experiments clearly indicate 
that the subendothelial area and mesangial matrix are accessi-
ble to some circulating antigens. The molecular mechanism of 
entrapment of large-latticed immune complexes in subendo-
thelial area and mesangial matrix remain unclear , but when 
these complexes are converted to small-latticed complexes 
(Ag,Ab1 or Ag2Ab2}, they are readily released from these areas. 
The seq uence of glomerular deposition of immune complexes 
was examined by transmission electron microscopy [33]. After 
t he injection of a single dose of immune complexes, electron 
dense deposits first appeared in the fenestrae of the endothelial 
cells. Deposits in the subendothelial area and in the m esa ngial 
area increased later. When the large- latticed complexes were 
no longer present in the circulation, the endothelial fenestrae 
became clear and subendothelia l deposits disappeared leaving 
only deposits in the mesangial matrix. By 96 hr after the 
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injection of complexes these deposits also disappeared . When 
immune complexes with reduced and alkylated antibodies were 
employed, these complexes persisted longer in circulation, as 
discussed above. The deposition of these complexes in glomeruli 
was enhanced as compared to the injection of an identical dose 
of immune complexes, prepared with intact antibody molecules. 
These observations collectively suggest that the large-latticed 
immune complexes are entrapped in endothelial fenestrae, rear-
range to become electron dense deposits visible by electron 
microscopy and are then translocated to the subendothelial 
area and from there to the mesangial matrix. The mechanisms 
for this apparent movement have not been examined. 
The mechanisms for removal of already deposited immune 
complexes from glomeruli has been of considerable interest. 
Since the mesangial cells participate in phagocytosis of some 
substances, they were thought to phagocytize also immune 
complexes. Electron microscopic studies, however, suggested 
that mesangial cells showed no evidence of phagocytosis of 
immune complexes [33,39]. This problem was resolved by ad-
ministration of immune complexes to irradiated, marrow cross-
transplanted normal and Chediak-Higashi mice [41]. Immune 
complexes were found only in the bone-marrow derived cells 
with giant lysosomes in the glomerular mesangium and not in 
the resident cells of the mesangium that lack the giant lyso-
somes. Therefore, the conclusion was reached that the mesan-
gial cells do not participate· in phagocytosis of deposited im-
mune complexes, fmthermore , the hypercellularity of the glo-
merular area resulted from influx of marrow-derived mono-
cytes. It is of interest that the accumulation of bone-marrow 
derived monocytes in glomeruli of experimental animals was 
associated with the development of proteinuria [ 42]. Thus, the 
marrow-derived Kupffer cells in the liver play an important 
role in clearing large-latticed, pathogenic immune complexes 
from the circulation. When these complexes are deposited in 
glomeruli, bone-marrow derived monocytes participate in dis-
posal of these deposited complexes. During this process of 
phagocytosis they may release lysosomal enzymes that cause 
damage to structural components of the glomeruli. 
The mechanisms for development of subepithelial deposits 
remained unclear. The recent and elegant experiments of 
Couser et al [ 43], however, indicate that at least with the Fx1A 
antigen, derived from the brush border of proximal renal tu-
bu les, the immune complexes with this antigen are locally 
formed in the subepithelial space and not deposited from the 
circulation. This possibility is supported by the finding of no 
circulating immune complexes in patients with m embranous 
glomerulonephritis, characterized by only subepithelial deposits 
of immune complexes [ 44,45]. These findings point again to the 
need to examine the nature and fate of antigens in human 
immune complex diseases. 
The deposition of circulating immune complexes in the skin 
may be governed by other principles, but experimental methods 
are on hand to examine this problem. 
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DISCUSSION 
DR. GIGLI: What is the significance in vivo of solubil ization of 
immune-complexes by C3? 
DR. MANNJK: Oul' feeling is that it may not have much sign'ificance 
in the whole animal. We have not, however, examined this question. 
DR. GIGLJ: The concept about the in-situ formation of immune 
complexes is very in teresting. Could you please comment on t he obser-
vation that DNA combines to the basement membrane in both the 
glomerulus and also in the skin. Is the rapid disappearance of DNA 
from the circulation, as you pointed out when it is injected alone, due 
to binding to these areas? 
DR. MANNIK: This is a n ru·ea we ar e very much interested in. We 
looked quant itatively where DNA goes and found that over 90% of it is 
accounted for in the liver. The curious thing is that, most likely, the 
breakdown occm·s not in the phagocytic cells, but on the cell surface by 
an exoenzym e. . 
DR. PROVOST: It is interesting that in some patients who have SLE 
one finds very high quantit ies of serum immune complexes, e.g., by the 
Raji cell assay, yet the clinical evidence of renal disease, as well as 
other manifestations of immune complexes, is really nonexistent. It 
may very well be that in-situ complex formation does play a big role in 
the clinical manifestation of thi disease. 
DR. GIGLT: Something that is very interesting is that nobody who 
uses the Clq binding assay takes into account the fact that DNA is a 
fantastic binder of Clq . 
DR. MAN NIK: That is the reason why many of us do not use Clq 
binding assays. 
DR. PROVOST: We're all measuring immune complexes in sera but 
what we just heru·d is that maybe there is some in-situ complex 
formation which we have no way of measuring with the tools we 
present ly use to evaluate immune complex disease. 
DR. JORDON: I'd better make a comment to defend the Clq binding 
assay. We did some studies with Fred McDuffy a few yeru·s ago, 
comparing several of these sensitive radio assays for measuring immune 
complexes. In lupus, for instance, the Raj i cell and Clq binding assay 
were almost identical. Do complement receptors in the kidneys play 
any role in the deposit ion of complexes there? 
DH. MANNIK: That has not been carefully sorted out. When you ask 
what cells have the receptors; thei1· presence has been claimed on all 
cells, but the best studies show them to be the epithelial cell, and that 
is, of course, outside the glomerular basement membrane. The com-
plexes, as I illustrated above, which had deposited in the lru·gest 
am ounts in glomeru li, ru·e the ones that were ineffective in complement 
fixation, and therefore their deposition is not mediated by complement 
receptors on glomerular structures. Others have suggested an Fe recep-
tor in glomeruli. Obviously some mechanism keeps the complexes, 
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when they are large enough, entrapped in glomeruli and they are 
released when converted to small complexes. 
its to see them. Some of the examples, I showed, in l hr after inj ection 
of immune complexes, one expects t hat some complexes are deposited; 
ye t by immunofluorescence or by electronmicroscopy we did not see 
them. Considered in terms of what must happen in the glomerulus, t he 
complexes in the circulation were between 11 and 19 Svedberg units. 
One can not really see these complexes by the kind of resolution used 
fo r electron microscopy of tissues. The electron dense deposits that one 
recognizes homs later are the result of further accumulation of com-
plexes or actual immune precipitate formation due to local concentra-
tion of complexes. 
DR. WUEPPE R: Many of us see deposits of the size and shape of . 
immune complexes at the locations where they may land in tissue, 
including skin, and freq uent ly see complement components but have 
great difficul ty demonstrating immunoglobins, which I presume are 
buried beneath these complement components . Curtis Wilson, for ex-
ample, at times has looked at kidneys with 125-I antigen and has been 
able to measure the label in the kidney. Yet, by no fluorescent ant ibody 
technique could he find antigen. 
DR. MANNIK: Obviously, one must have a minimal amount of depos-
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